Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to 32.39%.

  • Biodesix's EBITDA Margin rose 149400.0% to 32.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.61%, marking a year-over-year increase of 123500.0%. This contributed to the annual value of 48.37% for FY2024, which is 358500.0% up from last year.
  • As of Q3 2025, Biodesix's EBITDA Margin stood at 32.39%, which was up 149400.0% from 48.55% recorded in Q2 2025.
  • Biodesix's EBITDA Margin's 5-year high stood at 19.34% during Q1 2021, with a 5-year trough of 220.85% in Q1 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 74.38% (2024), whereas its average is 91.71%.
  • Per our database at Business Quant, Biodesix's EBITDA Margin skyrocketed by 1459300bps in 2021 and then plummeted by -2015000bps in 2022.
  • Over the past 5 years, Biodesix's EBITDA Margin (Quarter) stood at 161.67% in 2021, then increased by 11bps to 144.58% in 2022, then surged by 68bps to 46.84% in 2023, then surged by 31bps to 32.55% in 2024, then increased by 0bps to 32.39% in 2025.
  • Its EBITDA Margin was 32.39% in Q3 2025, compared to 48.55% in Q2 2025 and 50.87% in Q1 2025.